- Prize awarded by the Vienna Economic Chamber to the most
innovative companies in Vienna
- Ares Genetics´ awarded in the category Life Sciences for its
AI-powered Universal Pathogenome Assay - ARESupa
Vienna, Austria, and Holzgerlingen,
Germany, November 25, 2019, 10:00 am CET - Curetis N.V.
(the "Company" and, together with its
subsidiaries, "Curetis"), a developer of next-level molecular
diagnostic solutions, today announced that its fully-owned
subsidiary Ares Genetics was awarded the 2019 MERCUR Innovation
Prize by the Vienna Economic Chamber in the category Life
Sciences.
The prize was awarded for Ares Genetics’ ARESupa
– Universal Pathogenome Assay, a diagnostic tool for personalized
antibiotic resistance diagnostics combining next-generation
sequencing with artificial intelligence (AI).
Information on the antibiotic susceptibility of
pathogens is of utmost importance for clinical practice,
epidemiology and public health purposes as well as for the
development of pharmaceutical products in the infectious disease
sector. ARESupa accurately predicts antibiotic susceptibility via
AI-powered interpretation of high-throughput DNA sequencing data of
pathogens.
The MERCUR Innovation Prize is awarded every
year by the Vienna Economic Chamber to highlight and support the
innovation potential of Vienna’s enterprises. The prize awards
product or process innovations characterized by high practical
utility as well as economic impact in four categories, namely
Creativity and Media/Consulting, Life Sciences, Green Economy, and
ICT/Technology.
Ares Genetics’ R&D programs for the
development of ARESupa are co-funded by non-dilutive public grants
provided by the Vienna Business Agency, the Austrian Research
Promotion Agency (FFG), and other institutions with a total
co-funded volume of up to more than EUR 3 million.
“The entire Ares Genetics team is extremely
proud to be awarded this prestigious prize for its contribution to
the fight against spreading antibiotic resistance, one of the most
challenging threats to modern healthcare globally,” commented Dr.
Andreas Posch, Managing Director and CEO of Ares Genetics. ”We
would not have been able to pursue our innovative approach to
infectious disease diagnostics so successfully without the help of
our many supporters at the Vienna Economic Chamber, the Vienna
Business Agency, the Austrian Research Promotion Agency, Life
Science Austria, and the Vienna Biocenter, just to name a few.
Thank you all!”
###About
ARESupa Universal Pathogenome Assay
Information on antibiotic susceptibility of
pathogens is of utmost importance for clinical practice,
epidemiology and public health purposes as well as for the
development of pharmaceutical products in the infectious disease
sector. Ares Genetics therefore has developed a molecular
Antibiotic Susceptibility Test (AST) that is marketed under the
brand name ARESupa – Universal Pathogenome Assay and is capable of
accurately identifying microbial pathogens as well as predicting
antibiotic susceptibility via artificial intelligence-powered
interpretation of high-throughput DNA sequencing data obtained by
next-generation sequencing technologies.
ARESupa is based on whole-genome sequencing of
bacterial strains isolated from clinical specimens, combined with
data analysis and interpretation powered by ARESdb, Ares Genetics’
unique, proprietary reference database on genetic antimicrobial
resistance markers. ARESdb covers genomes of about 40,000 bacterial
strains and associated susceptibility data for more than 100
different antibiotics.
ARESupa already today performs in line with FDA
requirements for over 50 drug/pathogen combinations with prediction
algorithms for further drug/pathogen combinations in
development.
The test is initially offered for non-diagnostic
applications in epidemiology, infection control, and outbreak
analysis for customers in the public health sector and the
pharmaceutical industry. A laboratory-developed test (LDT) on
native patient samples for human diagnostic use in indications in
which current culture-based diagnostic practice is inherently
challenging is planned. Furthermore, Ares Genetics has recently
entered into a multi-phase strategic partnership with an
undisclosed leading global in vitro diagnostics corporation to
jointly develop diagnostic solutions for infectious disease testing
based on the ARESupa.For further information and quotes, please
register on the Ares Genetics cloud
platform:https://ares-genetics.cloud/or contactAres Genetics GmbH
Karl-Farkas-Gasse 18 A-1030 Wien AustriaEmail:
services@ares-genetics.com About Curetis and Ares
Genetics
Curetis N.V.’s (Euronext: CURE) goal is to
become a leading provider of innovative solutions for molecular
microbiology diagnostics designed to address the global challenge
of detecting severe infectious diseases and identifying antibiotic
resistances in hospitalized patients.
Curetis’ Unyvero System is a versatile, fast and
highly automated molecular diagnostic platform for easy-to-use,
cartridge-based solutions for the comprehensive and rapid detection
of pathogens and antimicrobial resistance markers in a range of
severe infectious disease indications. Results are available within
hours, a process that can take days or even weeks if performed with
standard diagnostic procedures, thereby facilitating improved
patient outcomes, stringent antibiotic stewardship and
health-economic benefits. Unyvero in vitro diagnostic (IVD)
products are marketed in Europe, the Middle East, Asia and the
U.S.
Curetis’ wholly owned subsidiary Ares Genetics
GmbH is developing next-generation solutions for infectious disease
diagnostics and therapeutics. The ARES Technology Platform combines
the presumably most comprehensive database worldwide on the
genetics of antimicrobial resistances, ARESdb, with advanced
bioinformatics and artificial intelligence.
For further information, please visit
www.curetis.com and www.ares-genetics.com.Legal
Disclaimer
This document constitutes neither an offer to
buy nor to subscribe securities and neither this document nor any
part of it should form the basis of any investment decision in
Curetis.
The information contained in this press release
has been carefully prepared. However, Curetis bears and assumes no
liability of whatever kind for the correctness and completeness of
the information provided herein. Curetis does not assume an
obligation of whatever kind to update or correct information
contained in this press release whether as a result of new
information, future events or for other reasons.
This press release includes statements that are,
or may be deemed to be, “forward-looking statements”. These
forward-looking statements can be identified by the use of
forward-looking terminology, including the terms “believes”,
“estimates”, “anticipates”, “expects”, “intends”, “may”, “will”, or
“should”, and include statements Curetis makes concerning the
intended results of its strategy. By their nature, forward-looking
statements involve risks and uncertainties and readers are
cautioned that any such forward-looking statements are not
guarantees of future performance. Curetis’ actual results may
differ materially from those predicted by the forward-looking
statements. Curetis undertakes no obligation to publicly update or
revise forward-looking statements, except as may be required by
law.
Contact Details
Curetis GmbHMax-Eyth-Str.
4271088 Holzgerlingen, GermanyTel. +49 7031 49195-10pr@curetis.com
or ir@curetis.com
www.curetis.com
Curetis International Media &
Investor InquiriesakampionDr. Ludger Wess / Ines-Regina
Buth Managing Partnersinfo@akampion.comTel. +49 40 88 16 59 64Tel.
+49 30 23 63 27 68
- 20191125_PR_Curetis_ARES_Mercur_Award_final._approved
Direxion Daily Healthcar... (AMEX:CURE)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Direxion Daily Healthcar... (AMEX:CURE)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024
